Virtual Library
Start Your Search
I.S. Yengkhom
Author of
-
+
P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.01-032 - Patterns of Care in Long Term Survivors (> 3 Years) in Advanced NSCLC- Retrospective Analysis of 30 Patients from a Single Institute (ID 2372)
09:30 - 09:30 | Author(s): I.S. Yengkhom
- Abstract
Background:
Long term survivors ( >3years) in advanced NSCLC is steadily increasing from 5 - 10% to 15 - 20%. It is related with the more effective and better treatment given in an individualised manner along with better understanding of the tumour biology. Many factors are also associated with the improved outcome. Our Institute’s 3 years data is analysed in an attempt to find out the favourable factors.
Methods:
Data mining of Stage III & IV non small cell lung cancers treated at RCC, RIMS during 2010 to 2012 are carried out from the patient’s departmental records. Only patients diagnosed and treated at RIMS who survive more than 3 years are included for analysis. Patient characteristics, disease profile & treatment pattern are analysed.
Results:
Out of 196 patients records available- Stage III & IV comprise 160 patients of these 30 patients survived more than 3 years. The analysis shows Male: Female ratio 5:4, mean age 55 years (range 36 to 90 yrs) stage III is 18(60%) stage IV 12(40%). Histologically, Squamous cell Ca. 60% Adeno ca. 24% and small cell 12% and rest others. KPS range from 60% to 90%. Treatment given: 80% received intent to cure with Chemo ± RT. And 20% palliative care only. Long survivors (>3years) 24 patients (16F + 8M) who received intent to treat chemo or chemo+ RT compared to none in supportive care only
Conclusion:
The result shows that females with Histo type adenocarcinoma who received therapy with Chemo + RT +/- targeted therapy with intent to treat are the long survivors according to this study. The study indicates that treatment should be given in a sub set of patients with advanced disease who are responders for increasing meaningful survival.
